Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Br J Haematol. 2014 Sep 8;167(4):487–499. doi: 10.1111/bjh.13066

Figure 7. Doxorubicin or vincristine enhanced the treatment effects of the MXD3 siRNA-αCD22 Ab-SPIO NPs in Reh cells in vitro.

Figure 7

Combination single treatment of the MXD3 siRNA-αCD22 Ab-SPIO NPs and doxorubicin or vincristine at the 50% inhibitory concentration (IC50) doses showed significantly enhanced cytotoxicity in Reh cells. Data were collected in triplicates, with 2 independent experiments (n = 6). Data as mean. MXD3 siRNA-αCD22 Ab-SPIO NPs only vs. MXD3 siRNA-αCD22 Ab-SPIO NPs + doxorubicin (****) p < 0.0000001, doxorubicin only vs. MXD3 siRNA-αCD22 Ab-SPIO NPs + doxorubicin (****) p = 0.0000032, MXD3 siRNA-αCD22 Ab-SPIO NPs only vs. MXD3 siRNA-αCD22 Ab-SPIO NPs + vincristine (****) p < 0.0001 and vincristine only vs. MXD3 siRNA-αCD22 Ab-SPIO NPs + vincristine (****) p < 0.0000001.

SPIO, superparamagnetic iron oxide; NP, nanoparticle; siRNA, small interfering RNA.